Votrient (Pazopanib) 400 mg

Approved for the treatment of:

• Advanced Renal Cell Carcinoma (RCC): Standard first-line treatment for kidney cancer.
• Advanced Soft Tissue Sarcoma (STS): For patients who have received prior chemotherapy.

Strength: 400 mg tablet.

Standard Dosage: 800 mg (two 400 mg tablets) taken once daily.

⚠️ CRITICAL WARNING - EMPTY STOMACH:

• 🚫 Take at least 1 hour before a meal.
• 🚫 Or take at least 2 hours after a meal.

Danger: Food increases systemic exposure to pazopanib, potentially leading to severe liver toxicity. Tablets must be swallowed whole; do not crush.

• Severe hepatic impairment.
• Pregnancy (Category D).
• Children under 2 years of age (risk of severe organ toxicity).

Notable side effects include:

• Hair Depigmentation: Hair turning white or grey is a common, harmless side effect.
• Hepatotoxicity: Regular monitoring of liver enzymes (ALT, AST, Bilirubin) is mandatory.
• Hypertension: Monitor blood pressure.
• Diarrhea and fatigue.